^
    2d
    Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors. (PubMed, Sci Adv)
    To demonstrate the usefulness of the method for immunotherapy applications, we investigated the interaction of primary multiple myeloma cells with the therapeutic monoclonal antibodies daratumumab and isatuximab and a polyclonal anti-CD38 antibody. Our approach might lay the foundation for improved personalized diagnostics and treatment with therapeutic antibodies.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule)
    |
    Darzalex (daratumumab) • Sarclisa (isatuximab-irfc)
    3d
    GMMG-HD7: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, University of Heidelberg Medical Center | Trial completion date: Mar 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection
    7d
    A multicenter prospective randomized controlled study of quadruplet regimen in newly diagnosed transplant-ineligible high-risk multiple myeloma patients (ChiCTR2600116772)
    P4, N=117, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    23d
    ISABELA: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    2ms
    Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, OHSU Knight Cancer Institute | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial primary completion date
    |
    carfilzomib • pomalidomide • Sarclisa (isatuximab-irfc)
    2ms
    The real-world safety profile and potential mechanism of isatuximab: Integration of pharmacovigilance and transcriptomic analysis. (PubMed, Medicine (Baltimore))
    By synergizing real-world pharmacovigilance with transcriptomic data, this study delineates novel clinical AE signals and mechanistic insights linking CD38-driven immunometabolic dysregulation to isatuximab toxicity. These findings underscore the imperative for vigilant monitoring and tailored therapeutic strategies to mitigate risks of immune dysfunction, informing both clinical practice and future biomarker-driven interventions.
    Journal • Adverse events • Real-world evidence • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Sarclisa (isatuximab-irfc)
    2ms
    Inflammatory Biomarkers for Thrombotic Risk Assessment in Multiple Myeloma Patients on IMiD/aCD38-Based Regimens: Insights from a Prospective Observational Study. (PubMed, Biomolecules)
    Treatment regimens comprised lenalidomide (n = 36) or thalidomide (n = 15) with daratumumab, and pomalidomide (n = 2) with isatuximab. Most patients (n = 38) received frontline therapy, and all were given thromboprophylaxis according to guidelines, mainly aspirin (73%)...Given the limited number of patients and thrombotic events, and the cytokine data available for only two VTE cases, these associations should be regarded as exploratory and interpreted with caution. Overall, these exploratory findings warrant validation in larger, independent cohorts and may help generate hypotheses on how inflammatory signatures influence thrombotic risk and prophylaxis efficacy in MM patients receiving IMiD/anti-CD38-based regimens.
    Observational data • Journal • IO biomarker
    |
    B2M (Beta-2-microglobulin) • CSF1 (Colony stimulating factor 1)
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • thalidomide • Sarclisa (isatuximab-irfc) • aspirin
    3ms
    Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=61, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    |
    lenalidomide • Sarclisa (isatuximab-irfc)
    3ms
    DREAMM 5: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=208, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2029 --> Mar 2027 | Trial primary completion date: Feb 2029 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Jemperli (dostarlimab-gxly) • dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat) • feladilimab (GSK3359609) • GSK3174998
    3ms
    Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. (PubMed, Pharmaceutics)
    The effects of IMiDs (pomalidomide, lenalidomide) on CD38 expression and isatuximab-induced apoptosis, either alone or in combination with IMiDs, were also examined. Additionally, both antibodies effectively inhibited MM cell migration and significantly reduced cell adhesion. Their non-competitive binding and shared impact on cell dynamics suggest opportunities for optimizing treatment strategies through combinatorial or sequential approaches in MM therapy.
    Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • ITGA4 (Integrin, alpha 4)
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • Sarclisa (isatuximab-irfc)
    4ms
    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    4ms
    UltraFrailMM: Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Utah | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • dexamethasone • Sarclisa (isatuximab-irfc)